S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
S&P 500   3,380.16 (+0.18%)
DOW   29,398.08 (-0.09%)
QQQ   234.64 (+0.29%)
Log in

LON:RLM - Realm Therapeutics Share Price, Forecast & News

Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume164,353 shs
Average Volume11,895 shs
Market Capitalization£13.41 million
P/E RatioN/A
Dividend YieldN/A
Realm Therapeutics Plc, a biopharmaceutical company, focuses on developing therapies for the treatment of immune-mediated diseases in adults and children. Its product pipeline includes PRO22, a topical gel, which is conducting initial Phase II clinical studies for the treatment of atopic dermatitis. The company was formerly known as PuriCore plc and changed its name to Realm Therapeutics Plc in December 2016. Realm Therapeutics Plc was founded in 2016 and is headquartered in Malvern, Pennsylvania.

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual Sales£501,919.00
Book ValueGBX 20.80 per share



Market Cap£13.41 million
Next Earnings DateN/A
OptionableNot Optionable

Receive RLM News and Ratings via Email

Sign-up to receive the latest news and ratings for RLM and its competitors with MarketBeat's FREE daily newsletter.

Realm Therapeutics (LON:RLM) Frequently Asked Questions

What is Realm Therapeutics' stock symbol?

Realm Therapeutics trades on the London Stock Exchange (LON) under the ticker symbol "RLM."

Has Realm Therapeutics been receiving favorable news coverage?

News headlines about RLM stock have trended extremely negative recently, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Realm Therapeutics earned a daily sentiment score of -5.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 6.0 out of 10, indicating that recent press coverage is somewhat likely to have an effect on the company's share price in the near future. View News Stories for Realm Therapeutics.

Who are some of Realm Therapeutics' key competitors?

What other stocks do shareholders of Realm Therapeutics own?

Who are Realm Therapeutics' key executives?

Realm Therapeutics' management team includes the folowing people:
  • Mr. John Alexander Martin, CEO & Exec. Director (Age 51)
  • Ms. Marella Thorell, CFO, COO, Company Sec. & Exec. Director (Age 52)
  • Dr. Christian Peters, Chief Medical Officer (Age 57)

How do I buy shares of Realm Therapeutics?

Shares of RLM and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

How big of a company is Realm Therapeutics?

Realm Therapeutics has a market capitalization of £0.00 and generates £501,919.00 in revenue each year. View Additional Information About Realm Therapeutics.

What is Realm Therapeutics' official website?

The official website for Realm Therapeutics is http://www.realmtx.com/.

How can I contact Realm Therapeutics?

Realm Therapeutics' mailing address is 508 Lapp Rd, MALVERN, PA 19355-1214, United States. The company can be reached via phone at +1-484-3212700.

MarketBeat Community Rating for Realm Therapeutics (LON RLM)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  149 (Vote Underperform)
Total Votes:  339
MarketBeat's community ratings are surveys of what our community members think about Realm Therapeutics and other stocks. Vote "Outperform" if you believe RLM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RLM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/17/2020 by MarketBeat.com Staff

Featured Article: Do You Need a Fiduciary?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel